Rhopressa, Aerie Pharmaceuticals

Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.
Novel glaucoma drug lowers IOP by unique combination of mechanismsIn a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.
Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
Drug therapies, delivery systems advance for glaucoma carePharmacologic products and devices in development continue to gain momentum in the glaucoma treatment armamentarium.
2015's glaucoma therapy advancesWhile no new drug shook up the world of glaucoma in 2015, a variety of promising agents made incremental advances toward the market with their true potential as yet unproven. Manufacturers have continued to refine approaches to existing drugs.
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
First-in-class glaucoma therapy shows promise in phase II studyTopical AR-13324 0.02% (Rhopressa, Aerie Pharmaceuticals) significantly lowered IOP in eyes with ocular hypertension or open-angle glaucoma in a 28-day phase II study.